Literature DB >> 8959988

Selegiline monotherapy in the treatment of Parkinson's disease.

W C Koller1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8959988     DOI： 10.1212/wnl.47.6_suppl_3.196s

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  2 in total

1.  Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.

Authors:  A Negrotti; G Bizzarri; S Calzetti
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

2.  Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Authors:  K Laine; M Anttila; A Helminen; H Karnani; R Huupponen
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.